◆ Market Data --:--
Commodities
Loading...
📈 Yields & Rates
Loading...
💱 FX Rates
Loading...
📈 Market Pulse
Loading...
🏛 Congress Trades
Loading...
👤 Insider Trades
Loading...

AGIOS PHARMACEUTICALS, INC.

CIK: 1439222 SIC: 2834
$54.03M
Revenue
$-412.78M
Net Income
88.26%
Gross Margin
-873.87%
Op. Margin
$-679.80M
Free Cash Flow
Financial Statements Annual (10-K)
Showing 5 of 13 annual reports available (2013 - 2025)
Breakdown TTM
(Dec 31, 2025)
FY 2025
(Dec 31, 2025)
FY 2024
(Dec 31, 2024)
FY 2023
(Dec 31, 2023)
FY 2022
(Dec 31, 2022)
FY 2021
(Dec 31, 2021)
+ Total Revenue $54.03M $54.03M $36.50M $26.82M $14.24M -
Revenue Growth % 0.0% 48.0% 36.1% 88.4% nan% nan%
Cost of Revenue $6.34M $6.34M $4.17M $2.88M $1.70M -
+ Gross Profit $47.68M $47.68M $32.33M $23.94M $12.54M -
Gross Margin % 88.3% 88.3% 88.6% 89.3% 88.0% nan%
Operating Expenses $526.16M $526.16M $462.24M $418.31M $403.29M $378.42M
Research & Development $339.54M $339.54M $301.29M $295.53M $279.91M $256.97M
Selling General & Admin $180.28M $180.28M $156.78M $119.90M $121.67M $121.44M
+ Operating Income $-472.13M $-472.13M $-425.74M $-391.49M $-389.05M $-378.42M
Operating Margin % -873.9% -873.9% -1166.5% -1459.5% -2732.1% nan%
Interest Income - - - - $12.79M $836.00K
Other Income/Expense $1.96M $1.96M $6.49M $6.05M $6.75M $14.43M
Income Before Tax - $-413.80M $717.97M $-352.09M $-231.80M $-356.51M
Income Tax Expense - $-1.02M $44.24M - - -
+ Net Income $-412.78M $-412.78M $673.73M $-352.09M $-231.80M $1.60B
Net Margin % -764.0% -764.0% 1845.9% -1312.6% -1627.8% nan%
Basic EPS -7.11 -7.12 11.86 -6.33 -4.23 26.55
Diluted EPS -7.11 -7.12 11.64 -6.33 -4.23 26.55
Basic Shares Outstanding - 58.0M 56.8M 55.7M 54.8M 60.4M
Diluted Shares Outstanding - 58.0M 57.9M 55.7M 54.8M 60.4M
Breakdown FY 2025
(Dec 31, 2025)
FY 2024
(Dec 31, 2024)
FY 2023
(Dec 31, 2023)
FY 2022
(Dec 31, 2022)
FY 2021
(Dec 31, 2021)
Cash & Cash Equivalents $89.13M $76.25M $88.20M $139.26M $203.13M
Inventory $32.92M $27.62M $19.08M $8.49M -
Other Current Assets $44.13M $40.16M $35.02M $38.95M $39.84M
Total Current Assets $942.05M $965.60M $833.84M $832.77M $1.06B
Property Plant & Equipment $10.78M $11.68M $15.38M $22.99M $28.92M
Other Non-current Assets $3.93M $4.72M $4.06M $3.96M $2.90M
Total Assets $1.30B $1.66B $937.12M $1.24B $1.44B
Accounts Payable $18.36M $16.64M $9.78M $18.62M $16.70M
Accrued Liabilities $45.46M $46.86M $43.17M $30.35M $31.97M
Total Current Liabilities $82.21M $81.16M $67.95M $62.63M $59.83M
Other Non-current Liabilities $90.00K $880.00K $1.16M $3.28M -
Total Liabilities $104.11M $122.24M $126.10M $137.90M $145.76M
Common Stock - - - - $71.00K
Retained Earnings $-561.71M $-148.92M $-822.65M $-470.56M $-238.76M
Treasury Stock $802.49M $802.49M $802.49M $802.49M $802.49M
Total Stockholders Equity $1.19B $1.54B $811.02M $1.10B $1.29B
Total Liabilities & Equity $1.30B $1.66B $937.12M $1.24B $1.44B
Breakdown TTM
(Dec 31, 2025)
FY 2025
(Dec 31, 2025)
FY 2024
(Dec 31, 2024)
FY 2023
(Dec 31, 2023)
FY 2022
(Dec 31, 2022)
FY 2021
(Dec 31, 2021)
Net Income $-502.07M $-412.78M $673.73M $-352.09M $-231.80M $1.60B
Stock-based Compensation $89.96M $52.55M $42.85M $44.77M $49.30M $53.51M
Change in Receivables $6.58M $6.47M $1.30M $604.00K $2.21M -
Change in Inventory $10.53M $5.30M $8.54M $10.58M $8.49M -
Change in Payables $9.00K $1.75M $6.60M $-8.73M $3.44M $1.86M
Operating Cash Flow $-673.08M $-372.98M $-389.84M $-296.06M $-309.48M $-407.32M
Capital Expenditure $6.72M $4.32M $1.69M $999.00K $4.88M $5.74M
Investing Cash Flow $681.32M $377.18M $363.44M $239.57M $243.26M $1.25B
Stock Issued - - - - - -
Stock Repurchased - - - - - $802.49M
Financing Cash Flow $11.98M $8.68M $14.44M $5.43M $2.35M $-765.77M
Net Change in Cash $20.22M $12.88M $-11.96M $-51.05M $-63.87M $75.69M
SEC Filing Format - Data shown as it appears in the Q3 2025 (10-Q) filing Period ended: Sep 30, 2025
Condensed Consolidated Statements of Operations
Description Sep 30, 2025 Sep 30, 2025
Current Prior Year Current YTD Prior Year YTD
Total Revenue $12.88M - $34.06M -
Cost of Revenue $1.68M - $4.47M -
Operating Expenses $129.75M - $384.62M -
Research & Development $86.80M - $251.48M -
Selling General & Admin $41.27M - $128.67M -
Operating Income $-116.87M - $-350.55M -
Other Income/Expense $67.00K - $1.84M -
Income Before Tax $-103.43M - $-304.74M -
Income Tax Expense - - - -
Net Income $-103.43M $-96.12M $-304.74M -
Basic EPS -1.78 - -5.27 -
Diluted EPS -1.78 - -5.27 -
Basic Shares Outstanding $58.14M - $57.85M -
Diluted Shares Outstanding $58.14M - $57.85M -
Condensed Consolidated Balance Sheets
Description Sep 30, 2025 Dec 31, 2024
Cash & Cash Equivalents $92.71M $76.25M
Inventory $32.03M $27.62M
Other Current Assets $43.19M $40.16M
Total Current Assets $1.03B $965.60M
Property Plant & Equipment $10.68M $11.68M
Other Non-current Assets $3.93M $4.72M
Total Assets $1.39B $1.66B
Accounts Payable $19.55M $16.64M
Accrued Liabilities $37.22M $46.86M
Total Current Liabilities $74.76M $81.16M
Other Non-current Liabilities $90.00K $880.00K
Total Liabilities $101.38M $122.24M
Retained Earnings $-453.67M $-148.92M
Treasury Stock $802.49M $802.49M
Total Stockholders Equity $1.28B $1.54B
Total Liabilities & Equity $1.39B $1.66B
Condensed Consolidated Statements of Cash Flows
Description Sep 30, 2025 Sep 30, 2025
Current Prior Year Current YTD Prior Year YTD
Net Income $-103.43M $-96.12M $-304.74M -
Stock-based Compensation - - $38.43M -
Change in Receivables - - $920.00K -
Change in Inventory - - $4.42M -
Change in Payables - - $2.89M -
Operating Cash Flow - - $-276.76M -
Capital Expenditure - - $3.20M -
Investing Cash Flow - - $287.11M -
Financing Cash Flow - - $6.12M -
Net Change in Cash - - $16.46M -

All values are in USD (United States Dollars). Data is sourced from SEC EDGAR 10-K filings.

Annual data represents full fiscal year results. FY = Fiscal Year ending.

NEWS
Loading news...
TRENDING
Loading...